文献速递头颈部肿瘤放疗

口咽癌根治性放疗中期的计算机断层扫描早期反应评估可预测局部区域复发

Early Response Assessment on Mid-treatment Computed Tomography Predicts for Locoregional Recurrence in Oropharyngeal Cancer Patients Treated With Definitive Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-06

该回顾性队列分析纳入2007至2015年在本机构接受根治性放疗的96例连续口咽癌患者,于第15次分次时重复CT扫描并勾画肿瘤体积。中位随访34个月,14例出现局部区域复发;总肿瘤体积缩小大于中位数(18.7%)是局部区域复发的独立预测因素(HR 0.22,95%CI 0.05-0.89;P=.020),原发肿瘤体积缩小预测作用更强(HR 0.11,95%CI 0.02-0.57;P=.002)。

要点

  • 中期CT评估的总肿瘤体积缩小大于中位数是局部区域复发的独立预测因素(HR 0.22)。
  • 原发肿瘤体积缩小对局部区域复发的预测作用更强(HR 0.11,95%CI 0.02-0.57;P=.002)。
  • 结合中期总肿瘤体积缩小≤中位数、p16阴性和吸烟>10包年可将患者分为高低危组,3年局部区域控制率分别为45.7%与90.7%。

核心结论

  • 中期CT扫描的早期治疗反应评估是局部区域复发的独立预测因素,可有效区分高危与低危患者,从而在治疗中途进行风险适应性分层。

研究设计与样本

  • 回顾性队列分析,纳入2007至2015年在本机构接受根治性放疗且有中期重复CT扫描的96例连续口咽癌患者。
  • 本机构头颈癌患者在放疗第15次分次时接受重复CT扫描,若总体疾病剂量不足或危及器官剂量增加则重新计划。
  • 在治疗前和中期CT上勾画原发疾病体积和受累淋巴结体积,采用单变量和多变量Cox比例风险回归分析评估中期肿瘤体积缩小对局部区域复发的预测效能。
  • 根据中期反应、p16状态和吸烟史将患者二分为高危组和低危组进行风险分层。

主要发现

  • 中位随访34个月,14例患者出现局部区域复发。
  • 总肿瘤体积中位缩小18.7%(四分位距8.4%-30.9%)。
  • 总肿瘤体积缩小大于中位数是局部区域复发的独立预测因素(HR 0.22,95%CI 0.05-0.89;P=.020)。
  • 原发肿瘤体积缩小对局部区域复发的预测作用更强(HR 0.11,95%CI 0.02-0.57;P=.002)。
  • 高危组(中期总肿瘤体积缩小≤中位数、p16阴性、吸烟>10包年)与低危组的Kaplan-Meier曲线明显分离,高危组3年局部区域控制率、无进展生存率和总生存率分别为45.7%、38.2%和71.8%,低危组分别为90.7%、70.6%和89.8%(所有P≤.021)。

关键数值与推荐

  • 总肿瘤体积缩小大于中位数(18.7%)为局部区域复发的独立预测因素(HR 0.22,95%CI 0.05-0.89;P=.020)。
  • 原发肿瘤体积缩小为局部区域复发的独立预测因素(HR 0.11,95%CI 0.02-0.57;P=.002)。
  • 高危组定义为中期总肿瘤体积缩小≤中位数、p16阴性、吸烟>10包年;低危组为不具备这些因素者。
  • 高危组3年局部区域控制率45.7%、无进展生存率38.2%、总生存率71.8%,低危组分别为90.7%、70.6%、89.8%(所有P≤.021)。

临床怎么用

  • 作者认为,中期CT扫描的早期治疗反应评估可有效区分高危和低危患者,允许在治疗中途进行风险适应性治疗分层。
  • 本研究中心的做法是头颈癌患者在放疗第15次分次时接受重复CT扫描,若总体疾病剂量不足或危及器官剂量增加则重新计划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate whether a response assessment using mid-treatment computed tomography (CT) scans during definitive radiation therapy (RT) for oropharyngeal head and neck cancer can predict for locoregional recurrence (LRR). METHODS AND MATERIALS: Head and neck cancer patients who receive RT at our institution undergo CT repeat scans at the 15th fraction, with treatment replanning in the case of an inadequate dose to gross disease or an increased dose to organs at risk. A retrospective cohort analysis was performed of 96 consecutive patients with oropharyngeal cancer treated from 2007 to 2015 with mid-treatment repeat CT scans available. The primary disease volume and involved lymph node volume were delineated on the pre- and mid-treatment CT scans. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate the efficacy of the mid-treatment reduction in tumor volume as a predictor of LRR. Risk stratification was performed by dichotomizing the patients into high- and low-risk groups according to the mid-treatment response and p16 status and smoking history. RESULTS: With a median follow-up of 34 months, 14 patients experienced LRR. The median reduction in the total tumor volume was 18.7% (interquartile range 8.4%-30.9%). A reduction in total tumor volume greater than the median was an independent predictor of LRR (hazard ratio 0.22, 95% confidence interval 0.05-0.89; P = .020). The reduction in primary tumor volume was an even stronger predictor of LRR (hazard ratio 0.11, 95% confidence interval 0.02-0.57; P = .002). Stratifying patients into a high-risk group for those with a reduction in the total tumor volume at mid-treatment at or less than the median, p16 negative status, and smoking status of >10 pack-years and a low-risk group for those without these factors, we found a clear separation in Kaplan-Meier curves, with actuarial 3-year locoregional control, progression-free survival, and overall survival rates for the high-risk patients of 45.7%, 38.2%, and 71.8% compared with 90.7%, 70.6%, and 89.8% for low-risk patients, respectively (P ≤ .021 for all). CONCLUSIONS: Our results have shown that the treatment response from an early assessment using mid-treatment CT scans is an independent predictor of LRR and can be used to effectively distinguish high- and low-risk patients, allowing for risk-adaptive treatment stratification at the midway point.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kabarriti R, Brodin NP, Lundgren G, et al. Early Response Assessment on Mid-treatment Computed Tomography Predicts for Locoregional Recurrence in Oropharyngeal Cancer Patients Treated With Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29779936. doi:10.1016/j.ijrobp.2018.03.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。